121 related articles for article (PubMed ID: 16847144)
1. JX401, A p38alpha inhibitor containing a 4-benzylpiperidine motif, identified via a novel screening system in yeast.
Friedmann Y; Shriki A; Bennett ER; Golos S; Diskin R; Marbach I; Bengal E; Engelberg D
Mol Pharmacol; 2006 Oct; 70(4):1395-405. PubMed ID: 16847144
[TBL] [Abstract][Full Text] [Related]
2. Discovery and characterization of a substrate selective p38alpha inhibitor.
Davidson W; Frego L; Peet GW; Kroe RR; Labadia ME; Lukas SM; Snow RJ; Jakes S; Grygon CA; Pargellis C; Werneburg BG
Biochemistry; 2004 Sep; 43(37):11658-71. PubMed ID: 15362850
[TBL] [Abstract][Full Text] [Related]
3. 3,4-Diaryl-isoxazoles and -imidazoles as potent dual inhibitors of p38alpha mitogen activated protein kinase and casein kinase 1delta.
Peifer C; Abadleh M; Bischof J; Hauser D; Schattel V; Hirner H; Knippschild U; Laufer S
J Med Chem; 2009 Dec; 52(23):7618-30. PubMed ID: 19591487
[TBL] [Abstract][Full Text] [Related]
4. High-throughput screening to identify inhibitors which stabilize inactive kinase conformations in p38alpha.
Simard JR; Grütter C; Pawar V; Aust B; Wolf A; Rabiller M; Wulfert S; Robubi A; Klüter S; Ottmann C; Rauh D
J Am Chem Soc; 2009 Dec; 131(51):18478-88. PubMed ID: 19950957
[TBL] [Abstract][Full Text] [Related]
5. Genetic analysis of p38 MAP kinases in myogenesis: fundamental role of p38alpha in abrogating myoblast proliferation.
Perdiguero E; Ruiz-Bonilla V; Gresh L; Hui L; Ballestar E; Sousa-Victor P; Baeza-Raja B; Jardí M; Bosch-Comas A; Esteller M; Caelles C; Serrano AL; Wagner EF; Muñoz-Cánoves P
EMBO J; 2007 Mar; 26(5):1245-56. PubMed ID: 17304211
[TBL] [Abstract][Full Text] [Related]
6. Preclinical pharmacokinetics and metabolism of 6-(4-(2,5-difluorophenyl)oxazol-5-yl)-3-isopropyl-[1,2,4]-triazolo[4,3-a]pyridine, a novel and selective p38alpha inhibitor: identification of an active metabolite in preclinical species and human liver microsomes.
Kalgutkar AS; Hatch HL; Kosea F; Nguyen HT; Choo EF; McClure KF; Taylor TJ; Henne KR; Kuperman AV; Dombroski MA; Letavic MA
Biopharm Drug Dispos; 2006 Nov; 27(8):371-86. PubMed ID: 16944451
[TBL] [Abstract][Full Text] [Related]
7. A one-step method to identify MAP kinase residues involved in inactivation by tyrosine- and dual-specificity protein phosphatases.
Tárrega C; Pulido R
Anal Biochem; 2009 Nov; 394(1):81-6. PubMed ID: 19583964
[TBL] [Abstract][Full Text] [Related]
8. The discovery of novel protein kinase inhibitors by using fragment-based high-throughput x-ray crystallography.
Gill A; Cleasby A; Jhoti H
Chembiochem; 2005 Mar; 6(3):506-12. PubMed ID: 15696598
[TBL] [Abstract][Full Text] [Related]
9. Mutagenesis of p38alpha MAP kinase establishes key roles of Phe169 in function and structural dynamics and reveals a novel DFG-OUT state.
Bukhtiyarova M; Karpusas M; Northrop K; Namboodiri HV; Springman EB
Biochemistry; 2007 May; 46(19):5687-96. PubMed ID: 17441692
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and biological activity of a focused library of mitogen-activated protein kinase phosphatase inhibitors.
Arnold DM; Foster C; Huryn DM; Lazo JS; Johnston PA; Wipf P
Chem Biol Drug Des; 2007 Jan; 69(1):23-30. PubMed ID: 17313454
[TBL] [Abstract][Full Text] [Related]
11. The antiproliferative effect of sildenafil on pulmonary artery smooth muscle cells is mediated via upregulation of mitogen-activated protein kinase phosphatase-1 and degradation of extracellular signal-regulated kinase 1/2 phosphorylation.
Li B; Yang L; Shen J; Wang C; Jiang Z
Anesth Analg; 2007 Oct; 105(4):1034-41, table of contents. PubMed ID: 17898384
[TBL] [Abstract][Full Text] [Related]
12. Biological evaluation and structural determinants of p38α mitogen-activated-protein kinase and c-Jun-N-terminal kinase 3 inhibition by flavonoids.
Goettert M; Schattel V; Koch P; Merfort I; Laufer S
Chembiochem; 2010 Dec; 11(18):2579-88. PubMed ID: 21108268
[TBL] [Abstract][Full Text] [Related]
13. Part 1: Structure-Activity Relationship (SAR) investigations of fused pyrazoles as potent, selective and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Wurz RP; Pettus LH; Xu S; Henkle B; Sherman L; Plant M; Miner K; McBride H; Wong LM; Saris CJ; Lee MR; Chmait S; Mohr C; Hsieh F; Tasker AS
Bioorg Med Chem Lett; 2009 Aug; 19(16):4724-8. PubMed ID: 19574047
[TBL] [Abstract][Full Text] [Related]
14. The discovery of (R)-2-(sec-butylamino)-N-(2-methyl-5-(methylcarbamoyl)phenyl) thiazole-5-carboxamide (BMS-640994)-A potent and efficacious p38alpha MAP kinase inhibitor.
Hynes J; Wu H; Pitt S; Shen DR; Zhang R; Schieven GL; Gillooly KM; Shuster DJ; Taylor TL; Yang X; McIntyre KW; McKinnon M; Zhang H; Marathe PH; Doweyko AM; Kish K; Kiefer SE; Sack JS; Newitt JA; Barrish JC; Dodd J; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1762-7. PubMed ID: 18313298
[TBL] [Abstract][Full Text] [Related]
15. Benzothiazole based inhibitors of p38alpha MAP kinase.
Liu C; Lin J; Pitt S; Zhang RF; Sack JS; Kiefer SE; Kish K; Doweyko AM; Zhang H; Marathe PH; Trzaskos J; Mckinnon M; Dodd JH; Barrish JC; Schieven GL; Leftheris K
Bioorg Med Chem Lett; 2008 Mar; 18(6):1874-9. PubMed ID: 18296051
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of p38alpha mitogen-activated protein kinase prevents the development of osteolytic bone disease, reduces tumor burden, and increases survival in murine models of multiple myeloma.
Vanderkerken K; Medicherla S; Coulton L; De Raeve H; Willems A; Lawson M; Van Camp B; Protter AA; Higgins LS; Menu E; Croucher PI
Cancer Res; 2007 May; 67(10):4572-7. PubMed ID: 17495322
[TBL] [Abstract][Full Text] [Related]
17. Improved expression, purification, and crystallization of p38alpha MAP kinase.
Bukhtiyarova M; Northrop K; Chai X; Casper D; Karpusas M; Springman E
Protein Expr Purif; 2004 Sep; 37(1):154-61. PubMed ID: 15294293
[TBL] [Abstract][Full Text] [Related]
18. A novel cell type-specific role of p38alpha in the control of autophagy and cell death in colorectal cancer cells.
Comes F; Matrone A; Lastella P; Nico B; Susca FC; Bagnulo R; Ingravallo G; Modica S; Lo Sasso G; Moschetta A; Guanti G; Simone C
Cell Death Differ; 2007 Apr; 14(4):693-702. PubMed ID: 17159917
[TBL] [Abstract][Full Text] [Related]
19. Discovery and evaluation of 7-alkyl-1,5-bis-aryl-pyrazolopyridinones as highly potent, selective, and orally efficacious inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Wurz RP; Xu S; Herberich B; Henkle B; Liu Q; McBride HJ; Mu S; Plant MH; Saris CJ; Sherman L; Wong LM; Chmait S; Lee MR; Mohr C; Hsieh F; Tasker AS
J Med Chem; 2010 Apr; 53(7):2973-85. PubMed ID: 20218619
[TBL] [Abstract][Full Text] [Related]
20. 3-amino-7-phthalazinylbenzoisoxazoles as a novel class of potent, selective, and orally available inhibitors of p38alpha mitogen-activated protein kinase.
Pettus LH; Xu S; Cao GQ; Chakrabarti PP; Rzasa RM; Sham K; Wurz RP; Zhang D; Middleton S; Henkle B; Plant MH; Saris CJ; Sherman L; Wong LM; Powers DA; Tudor Y; Yu V; Lee MR; Syed R; Hsieh F; Tasker AS
J Med Chem; 2008 Oct; 51(20):6280-92. PubMed ID: 18817364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
